p53 peptide-pulsed autologous dendritic cell vaccine

This is an autologous dendritic cell-based cancer vaccine developed by the National Cancer Institute (NCI) for the treatment of ovarian adenocarcinoma. The vaccine is prepared by pulsing a patient's own dendritic cells with the wild-type p53:264-272 peptide, which is a specific epitope of the p53 protein often overexpressed in ovarian cancer cells. The goal of the therapy is to induce a robust T-cell mediated immune response against tumor cells presenting p53 antigens. In clinical trials, such as those conducted by the Gynecologic Oncology Group, the vaccine was administered intravenously, often in combination with interleukin-2 (IL-2) to enhance the immunologic response and sustain T-cell activity.

Other names

autologous dendritic cells-National Cancer Institute (NCI)-ovarian adenocarcinomap53:264-272 peptide-pulsed dendritic cellstherapeutic autologous dendritic cellsp53-pulsed dendritic cell vaccinep-53-pulsed dendritic cell vaccinep 53-pulsed dendritic cell vaccine